Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.

Journal of hepatology - 1 Aug 2014

Hayashi Norio, Izumi Namiki, Kumada Hiromitsu, Okanoue Takeshi, Tsubouchi Hirohito, Yatsuhashi Hiroshi, Kato Mai, Ki Rito, Komada Yuji, Seto Chiharu, Goto Shoichiro

Abstract excerpt

BACKGROUND & AIMS: In a Japanese Phase II study, the hepatitis C virus NS3/4A protease inhibitor simeprevir demonstrated potent antiviral activity and significantly improved sustained virologic response rates when added to peginterferon α-2a/ribavirin in treatment-naïve patients infected with hepatitis C virus genotype 1. METHODS: CONCERTO-1 was a Phase III, randomized, double-blind, placebo-controlled trial....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Double-Blind Method
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Simeprevir

Share to Sulfonamides

Share to Treatment Failure

Source

Identifiers

PMID: 24727123
DOI: 10.1016/j.jhep.2014.04.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.PMID 24727123Read ↗

Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis.Semantic proximity Read ↗

[A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].Semantic proximity Read ↗

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.Semantic proximity Read ↗

Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.Semantic proximity Read ↗

Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.Semantic proximity Read ↗

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.Semantic proximity Read ↗

Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized trials.Semantic proximity Read ↗

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.Semantic proximity Read ↗

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.Semantic proximity Read ↗

Simeprevir for the treatment of chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.